BERGENBIO ASA (BGBIO.OL) Stock Fundamental Analysis
Europe • Euronext Oslo • OSL:BGBIO • NO0013251173
1.198 NOK
+0.07 (+5.83%)
Last: Oct 30, 2025, 03:44 PM
Taking everything into account, BGBIO scores 3 out of 10 in our fundamental rating. BGBIO was compared to 85 industry peers in the Biotechnology industry. BGBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, BGBIO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year BGBIO has reported negative net income.
- BGBIO had a negative operating cash flow in the past year.
- In the past 5 years BGBIO always reported negative net income.
- BGBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- BGBIO has a Return On Assets of -160.55%. This is amonst the worse of the industry: BGBIO underperforms 86.84% of its industry peers.
- The Return On Equity of BGBIO (-207.87%) is worse than 61.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -160.55% | ||
| ROE | -207.87% | ||
| ROIC | N/A |
ROA(3y)-126.61%
ROA(5y)-96.68%
ROE(3y)-201.42%
ROE(5y)-144.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for BGBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BGBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BGBIO has more shares outstanding
- Compared to 5 years ago, BGBIO has less shares outstanding
- BGBIO has a worse debt/assets ratio than last year.
2.2 Solvency
- BGBIO has an Altman-Z score of -3.91. This is a bad value and indicates that BGBIO is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -3.91, BGBIO is doing worse than 67.11% of the companies in the same industry.
- BGBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.91 |
ROIC/WACCN/A
WACC8.49%
2.3 Liquidity
- BGBIO has a Current Ratio of 4.39. This indicates that BGBIO is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 4.39, BGBIO is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
- BGBIO has a Quick Ratio of 4.39. This indicates that BGBIO is financially healthy and has no problem in meeting its short term obligations.
- With a decent Quick ratio value of 4.39, BGBIO is doing good in the industry, outperforming 76.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.39 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 70.32% over the past year.
- Looking at the last year, BGBIO shows a very strong growth in Revenue. The Revenue has grown by 139.55%.
- The Revenue for BGBIO have been decreasing by -37.51% on average. This is quite bad
EPS 1Y (TTM)70.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.07%
Revenue 1Y (TTM)139.55%
Revenue growth 3Y3.09%
Revenue growth 5Y-37.51%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to decrease by -15.45% on average over the next years. This is quite bad
- The Revenue is expected to grow by 210.58% on average over the next years. This is a very strong growth
EPS Next Y17.6%
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%
EPS Next 5Y-15.45%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y210.58%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- BGBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year BGBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as BGBIO's earnings are expected to decrease with -17.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%
5. Dividend
5.1 Amount
- No dividends for BGBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BERGENBIO ASA / BGBIO.OL FAQ
Can you provide the ChartMill fundamental rating for BERGENBIO ASA?
ChartMill assigns a fundamental rating of 3 / 10 to BGBIO.OL.
What is the valuation status of BERGENBIO ASA (BGBIO.OL) stock?
ChartMill assigns a valuation rating of 0 / 10 to BERGENBIO ASA (BGBIO.OL). This can be considered as Overvalued.
Can you provide the profitability details for BERGENBIO ASA?
BERGENBIO ASA (BGBIO.OL) has a profitability rating of 0 / 10.
How financially healthy is BERGENBIO ASA?
The financial health rating of BERGENBIO ASA (BGBIO.OL) is 6 / 10.
Can you provide the expected EPS growth for BGBIO stock?
The Earnings per Share (EPS) of BERGENBIO ASA (BGBIO.OL) is expected to grow by 17.6% in the next year.